These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 19419253

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
    Johnston SC.
    Nat Clin Pract Neurol; 2006 Jan; 2(1):24-5. PubMed ID: 16932517
    [No Abstract] [Full Text] [Related]

  • 7. Prospects for the prevention of stroke.
    Dahlöf B.
    J Hypertens Suppl; 2006 Apr; 24(2):S3-9. PubMed ID: 16601558
    [Abstract] [Full Text] [Related]

  • 8. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Larsen K, Hornnes N, Boysen G.
    Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
    [No Abstract] [Full Text] [Related]

  • 9. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [Abstract] [Full Text] [Related]

  • 10. The role of RAS modification for primary and secondary stroke prevention.
    Fintel DJ.
    Postgrad Med; 2009 Jul; 121(4):115-22. PubMed ID: 19641277
    [Abstract] [Full Text] [Related]

  • 11. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A, Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of eprosartan on target organ protection.
    de la Sierra A.
    Vasc Health Risk Manag; 2006 Nov; 2(1):79-85. PubMed ID: 17319472
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S, Hammersen F, Kulschewski A, Frerichs A, Frieg R, Hahnheiser D, Reich G, Schnieders M, Schrandt G, Schrader J.
    Dtsch Med Wochenschr; 2006 Nov 17; 131(46):2580-5. PubMed ID: 17096303
    [Abstract] [Full Text] [Related]

  • 17. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul 17; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 18. [Hypertension 2007-2008].
    Chatzikyrkou C, Menne J, Haller H.
    Med Klin (Munich); 2009 Aug 17; 104(8):614-21. PubMed ID: 19701732
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.